Assaf Buch1, Eli Carmeli2, Lital Keinan Boker3, Yonit Marcus4, Gabi Shefer4, Ofer Kis5, Yitshal Berner6, Naftali Stern4. 1. Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel; The Sackler Faculty of Medicine, Tel-Aviv University, Israel. Electronic address: buchasaf@gmail.com. 2. Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel; School of Public Health, Haifa University, Haifa, Israel. 3. School of Public Health, Haifa University, Haifa, Israel. 4. Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel; The Sackler Faculty of Medicine, Tel-Aviv University, Israel. 5. Institute of Endocrinology, Metabolism and Hypertension, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel. 6. The Sackler Faculty of Medicine, Tel-Aviv University, Israel; Meir Medical Center, Kfar Saba, Israel.
Abstract
BACKGROUND AND AIM: In western countries, the proportion of people over age 60 is increasing faster than any other group. This is linked to higher rates of obesity. Older age, co-morbidities and obesity are all associated with frailty syndrome. In the core of both frailty and sarcopenia there are dysfunction and deterioration of the muscle and the fat tissues. This overview interlinks the phenotypes presented in older adults such as sarcopenia and frailty-alone and with relation to obesity, muscle function and fat tissue accumulation. RECENT FINDINGS: Observational studies have well described the loss of muscle mass and strength through the years of adult life, both components of frailty and sarcopenia. They have shown that these changes are associated with dysmetabolism and functional deterioration, independent of common explanatory variables. In the metabolic mechanism core of this link, insulin resistance and higher ectopic fat accumulation may play a role. Basic experiments have partially validated this hypothesis. Whether there is a synergistic effect of obesity and frailty phenotype on morbidity risk is still questionable and currently under investigation; however, few cohort studies have shown that the frail-obese or sarcopenic-obese group have higher probability for metabolic complications. SUMMARY: Muscle mass loss and fat accumulation in the muscle in the elderly, with or without the presence of obesity, may explain some of the functional and metabolic defects shown in the frail, sarcopenic population.
BACKGROUND AND AIM: In western countries, the proportion of people over age 60 is increasing faster than any other group. This is linked to higher rates of obesity. Older age, co-morbidities and obesity are all associated with frailty syndrome. In the core of both frailty and sarcopenia there are dysfunction and deterioration of the muscle and the fat tissues. This overview interlinks the phenotypes presented in older adults such as sarcopenia and frailty-alone and with relation to obesity, muscle function and fat tissue accumulation. RECENT FINDINGS: Observational studies have well described the loss of muscle mass and strength through the years of adult life, both components of frailty and sarcopenia. They have shown that these changes are associated with dysmetabolism and functional deterioration, independent of common explanatory variables. In the metabolic mechanism core of this link, insulin resistance and higher ectopic fat accumulation may play a role. Basic experiments have partially validated this hypothesis. Whether there is a synergistic effect of obesity and frailty phenotype on morbidity risk is still questionable and currently under investigation; however, few cohort studies have shown that the frail-obese or sarcopenic-obese group have higher probability for metabolic complications. SUMMARY: Muscle mass loss and fat accumulation in the muscle in the elderly, with or without the presence of obesity, may explain some of the functional and metabolic defects shown in the frail, sarcopenic population.
Authors: Rabia Asghar; Maria Chondronikola; Edgar L Dillon; William J Durham; Craig Porter; Zhanpin Wu; Maria Camacho-Hughes; Clark R Andersen; Heidi Spratt; Elena Volpi; Melinda Sheffield-Moore; Labros Sidossis; Robert R Wolfe; Nicola Abate; Demidmaa R Tuvdendorj Journal: J Lipid Res Date: 2018-08-21 Impact factor: 5.922
Authors: Peter Krustrup; Eva Wulff Helge; Peter R Hansen; Per Aagaard; Marie Hagman; Morten B Randers; Maysa de Sousa; Magni Mohr Journal: Eur J Appl Physiol Date: 2017-11-21 Impact factor: 3.078
Authors: Elena Ongaro; Vanessa Buoro; Marika Cinausero; Riccardo Caccialanza; Annalisa Turri; Valentina Fanotto; Debora Basile; Maria Grazia Vitale; Paola Ermacora; Giovanni Gerardo Cardellino; Laura Nicoletti; Lorenzo Fornaro; Andrea Casadei-Gardini; Giuseppe Aprile Journal: Gastric Cancer Date: 2017-05-05 Impact factor: 7.370
Authors: Daniel A Galvão; Dennis R Taaffe; Nigel Spry; Robert A Gardiner; Renea Taylor; Gail P Risbridger; Mark Frydenberg; Michelle Hill; Suzanne K Chambers; Phillip Stricker; Tom Shannon; Dickon Hayne; Eva Zopf; Robert U Newton Journal: Nat Rev Urol Date: 2016-03-08 Impact factor: 14.432
Authors: Ran Li; Jin Xia; X I Zhang; Wambui Grace Gathirua-Mwangi; Jianjun Guo; Yufeng Li; Steve McKenzie; Yiqing Song Journal: Med Sci Sports Exerc Date: 2018-03 Impact factor: 5.411
Authors: Shawna Follis; Alan Cook; Jennifer W Bea; Scott B Going; Deepika Laddu; Jane A Cauley; Aladdin H Shadyab; Marcia L Stefanick; Zhao Chen Journal: J Am Geriatr Soc Date: 2018-10-30 Impact factor: 5.562